Individuals with psychotic depression experience the symptoms of a major depressive episode, along with one or more psychotic symptoms, including delusions and/or hallucinations. Delusions can be classified as mood congruent or incongruent, depending on whether or not the nature of the delusions is in keeping with the individual's mood state. Common themes of mood congruent delusions include guilt, punishment, personal inadequacy, or disease. Half of patients experience more than one kind of delusion. Delusions occur without hallucinations in about one-half to two-thirds of patients with psychotic depression. Hallucinations can be auditory, visual, olfactory (smell), or haptic (touch). Severe anhedonia, loss of interest, and psychomotor retardation are typically present.
Psychotic symptoms tend to develop after an individual has already had several episodes of depression without psychosis. However, once psychotic symptoms have emerged, they tend to reappear with each future depressive episode. The prognosis for psychotic depression is not considered to be as poor as for schizoaffective disorders or primary psychotic disorders. Still, those who have experienced a depressive episode with psychotic features have an increased risk of relapse and suicide compared to those without psychotic features, and they tend to have more pronounced sleep abnormalities.
The families of those who have experienced psychotic depression are at increased risk for both psychotic depression and schizophrenia.
Most patients with psychotic depression report having an initial episode between the ages of 20 and 40. Over a lifetime, it appears that patients with psychotic depression experience an average of 4 to 9 episodes. As with other depressive episodes, psychotic depression tends to be episodic, with symptoms lasting for a certain amount of time and then subsiding. While psychotic depression can be chronic (lasting more than 2 years), most depressive episodes last less than 24 months. Unlike psychotic disorders such as schizophrenia and schizoaffective disorder, patients with psychotic depression generally function well between episodes, both socially and professionally.
Psychotic symptoms are often missed in psychotic depression, either because patients do not think their symptoms are abnormal or they attempt to conceal their symptoms from others. On the other hand, psychotic depression may be confused with schizoaffective disorder.
There are a number of biological features that may distinguish psychotic depression from non-psychotic depression. The most significant difference may be the presence of an abnormality in the hypothalamic pituitary adrenal axis (HPA) axis. The HPA axis appears to be dysregulated in psychotic depression, with dexamethasone suppression tests demonstrating higher levels of cortisol following dexamethasone administration (i.e. lower cortisol suppression). Those with psychotic depression also have higher ventricular-brain ratios than those with non-psychotic depression.
Pharmaceutical treatments can include tricyclic antidepressants, atypical antipsychotics, or a combination of an antidepressant from the newer, more well tolerated SSRI or SNRI categories and an atypical antipsychotic.Olanzapine may be an effective monotherapy in psychotic depression, although there is evidence that it is ineffective for depressive symptoms as a monotherapy; and olanzapine/fluoxetine is more effective. Quetiapine monotherapy may be particularly helpful in psychotic depression since it has both antidepressant and antipsychotic effects and a reasonable tolerability profile compared to other atypical antipsychotics. The current drug-based treatments of psychotic depression are reasonably effective but can cause side effects, such as nausea, headaches, dizziness, and weight gain. Tricyclic antidepressants are particularly dangerous in overdose due to their potential to cause potentially-fatal cardiac arrhythmias.
In the context of psychotic depression, the following are the most well-studied antidepressant/antipsychotic combinations
In modern practice of ECT a therapeutic clonic seizure is induced by electrical current via electrodes placed on an anaesthetised, unconscious patient. Despite much research the exact mechanism of action of ECT is still not known. ECT carries the risk of temporary cognitive deficits (e.g., confusion, memory problems), in addition to the burden of repeated exposures to general anesthesia.
Among the newer experimental treatments is the study of glucocorticoid antagonists, including mifepristone. These strategies may treat the underlying pathophysiology of psychotic depression by correcting an overactive HPA axis. By competitively blocking certain neuro-receptors, these medications render cortisol less able to directly act on the brain.
Transcranial magnetic stimulation (TMS) is being investigated as an alternative to ECT in the treatment of depression. TMS involves the administration of a focused electromagnetic field to the cortex to stimulate specific nerve pathways.
Research has shown that psychotic depression differs from non-psychotic depression in a number of ways: potential precipitating factors, underlying biology, symptomatology beyond psychotic symptoms, long-term prognosis, and responsiveness to psychopharmacological treatment and ECT.
The long-term outcome for psychotic depression is generally poorer than for non-psychotic depression.
^ abcdefghijklmnopqHales E and Yudofsky JA, eds, The American Psychiatric Press Textbook of Psychiatry, Washington, DC: American Psychiatric Publishing, Inc., 2003
^American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington DC: American Psychiatric Association. ISBN978-0890420256.
^Leadholm, Anne Katrine K.; Rothschild, Anthony J.; Nolen, Willem A.; Bech, Per; Munk-Jørgensen, Povl; Ostergaard, Søren Dinesen (2013). "The treatment of psychotic depression: Is there consensus among guidelines and psychiatrists?". Journal of Affective Disorders145 (2): 214–20. doi:10.1016/j.jad.2012.07.036. PMID23021823.
^ abcRothschild, Anthony J.; Williamson, Douglas J.; Tohen, Mauricio F.; Schatzberg, Alan; Andersen, Scott W.; Van Campen, Luann E.; Sanger, Todd M.; Tollefson, Gary D. (August 2004). "A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". The Journal of Clinical Psychopharmacology24 (4): 365–373. doi:10.1097/01.jcp.0000130557.08996.7a. PMID15232326.
^Weisler, R; Joyce, M; McGill, L; Lazarus, A; Szamosi, J; Eriksson, H; Moonstone Study, Group (2009). "Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study". CNS spectrums14 (6): 299–313. PMID19668121.
^Bortnick, Brian; El-Khalili, Nizar; Banov, Michael; Adson, David; Datto, Catherine; Raines, Shane; Earley, Willie; Eriksson, Hans (2011). "Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study". Journal of Affective Disorders128 (1–2): 83–94. doi:10.1016/j.jad.2010.06.031. PMID20691481.
^Spiker, DG; Weiss, JC; Dealy, RS; Griffin, SJ; Hanin, I; Neil, JF; Perel, JM; Rossi, AJ; Soloff, PH (1985). "The pharmacological treatment of delusional depression". American Journal of Psychiatry142 (4): 430–436. PMID3883815.
^Muller-Siecheneder, Florian; Muller, Matthias J.; Hillert, Andreas; Szegedi, Armin; Wetzel, Hermann; Benkert, Otto (1998). "Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome". The Journal of Clinical Psychopharmacology18 (2): 111–120. doi:10.1097/00004714-199804000-00003. PMID9555596.
^Rothschild, Anthony J.; Williamson, Douglas J.; Tohen, Mauricio F.; Schatzberg, Alan; Andersen, Scott W.; Van Campen, Luann E.; Sanger, Todd M.; Tollefson, Gary D. (2004). "A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". The Journal of Clinical Psychopharmacology24 (2): 365–373. doi:10.1097/01.jcp.0000130557.08996.7a. PMID15232326.
^Belanoff, Joseph K.; Flores, Benjamin H.; Kalezhan, Michelle; Sund, Brenda; Schatzberg, Alan F. (October 2001). "Rapid reversal of psychotic depression using mifepristone". Journal of Clinical Psychopharmacology21 (5): 516–21. doi:10.1097/00004714-200110000-00009. PMID11593077.
^Ostergaard, SD; Rothschild, AJ; Uggerby, P; Munk-Jørgensen, P; Bech, P; Mors, O (2012). "Considerations on the ICD-11 classification of psychotic depression". Psychotherapy and psychosomatics81 (3): 135–44. doi:10.1159/000334487. PMID22398817.
^Østergaard, Søren Dinesen; Petrides, Georgios; Dinesen, Peter Thisted; Skadhede, Søren; Bech, Per; Munk-Jørgensen, Povl; Nielsen, Jimmi (2013). "The Association between Physical Morbidity and Subtypes of Severe Depression". Psychotherapy and Psychosomatics82 (1): 45–52. doi:10.1159/000337746. PMID23147239.
^Østergaard, Søren Dinesen; Waltoft, Berit Lindum; Mortensen, Preben Bo; Mors, Ole (2013). "Environmental and familial risk factors for psychotic and non-psychotic severe depression". Journal of Affective Disorders147 (1–3): 232–40. doi:10.1016/j.jad.2012.11.009. PMID23228568.
^Domschke, Katharina; Lawford, Bruce; Young, Ross; Voisey, Joanne; Morris, C. Phillip; Roehrs, Tilmann; Hohoff, Christa; Birosova, Eva; Arolt, Volker; Baune, Bernhard T. (2011). "Dysbindin (DTNBP1) – A role in psychotic depression?". Journal of Psychiatric Research45 (5): 588–95. doi:10.1016/j.jpsychires.2010.09.014. PMID20951386.
^Nelson, JC; Davis, JM (1997). "DST studies in psychotic depression: A meta-analysis". The American Journal of Psychiatry154 (11): 1497–503. PMID9356556.
^Posener, JA; Debattista, C; Williams, GH; Chmura Kraemer, H; Kalehzan, BM; Schatzberg, AF (2000). "24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression". Archives of General Psychiatry57 (8): 755–60. doi:10.1001/archpsyc.57.8.755. PMID10920463.
^Maj, M; Pirozzi, R; Magliano, L; Fiorillo, A; Bartoli, L (2007). "Phenomenology and prognostic significance of delusions in major depressive disorder: A 10-year prospective follow-up study". The Journal of clinical psychiatry68 (9): 1411–7. doi:10.4088/JCP.v68n0913. PMID17915981.
^Østergaard, SD; Bille, J; Søltoft-Jensen, H; Lauge, N; Bech, P (2012). "The validity of the severity-psychosis hypothesis in depression". Journal of Affective Disorders140 (1): 48–56. doi:10.1016/j.jad.2012.01.039. PMID22381953.
^Coryell, W; Leon, A; Winokur, G; Endicott, J; Keller, M; Akiskal, H; Solomon, D (1996). "Importance of psychotic features to long-term course in major depressive disorder". The American Journal of Psychiatry153 (4): 483–9. PMID8599395.
^Ostergaard, SD; Bertelsen, A; Nielsen, J; Mors, O; Petrides, G (2013). "The association between psychotic mania, psychotic depression and mixed affective episodes among 14,529 patients with bipolar disorder". Journal of Affective Disorders147 (1–3): 44–50. doi:10.1016/j.jad.2012.10.005. PMID23122529.